Research Report Screener Results

Chart, Financials, Historical Prices, Industry, Insider, Messages, Profile, Reports, Research, more...

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 9-Feb-2010
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 6 of 6)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
6-Feb-10 Reuters Investment Profile N/A DOV Pharmaceutical Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
30-Mar-09 ValuEngine, Inc. N/A ValuEngine Industry Report for DRUGS 18 $49 View Abstract
29-Mar-09 PriceTarget Research, Inc. N/A Health Care Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. 65 $40 View Abstract
28-Mar-09 Pechala's Reports Lubomir Pechala DOV PHARMACEUTICAL INC (DOVP=US) 2-weeks forecast 1 $10 View Abstract
28-Mar-09 Standard & Poor's Quantitative Report N/A DOV Pharmaceutical 5 $25 View Abstract
1-Sep-07 ValuEngine, Inc. N/A ValuEngine Detailed Valuation Report for DOVP 13 $25 View Abstract

Independent Reports (Showing 1 to 6 of 6)

Release
Date Contributor Author Title Pages Price More Info
6-Feb-10 Reuters Investment Profile N/A DOV Pharmaceutical Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
30-Mar-09 ValuEngine, Inc. N/A ValuEngine Industry Report for DRUGS 18 $49 View Abstract
29-Mar-09 PriceTarget Research, Inc. N/A Health Care Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. 65 $40 View Abstract
28-Mar-09 Pechala's Reports Lubomir Pechala DOV PHARMACEUTICAL INC (DOVP=US) 2-weeks forecast 1 $10 View Abstract
28-Mar-09 Standard & Poor's Quantitative Report N/A DOV Pharmaceutical 5 $25 View Abstract
1-Sep-07 ValuEngine, Inc. N/A ValuEngine Detailed Valuation Report for DOVP 13 $25 View Abstract

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.